High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

July 5, 2016

Primary Completion Date

June 19, 2019

Study Completion Date

February 1, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Carfilzomib

DRUG

Cyclophosphamide

DRUG

Dexamethasone

Trial Locations (9)

T6G 1Z2

Cross Cancer Institute, Edmonton

E2L 4L2

Regional Health Authority B, Zone 2, Saint John

B3H 1V7

QEII Health Sciences Centre, Halifax

K7L 2V7

Kingston Health Sciences Centre, Kingston

N6A 5W9

London Regional Cancer Program, London

K1H 8L6

Ottawa Hospital Research Institute, Ottawa

M5G 2M9

University Health Network, Toronto

H1T 2M4

CIUSSS de l'Est-de-I'lle-de-Montreal, Montreal

G1R 2J6

CHUQ-Pavillon Hotel-Dieu de Quebec, Québec

Sponsors
All Listed Sponsors
collaborator

Amgen

INDUSTRY

collaborator

Canadian Myeloma Research Group

OTHER

lead

Canadian Cancer Trials Group

NETWORK